JAZZ - Jazz Pharmaceuticals Public Limited Company

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
138.97
+4.14 (+3.07%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close134.83
Open134.94
Bid95.82 x 100
Ask142.24 x 100
Day's Range134.09 - 139.16
52 Week Range101.44 - 163.75
Volume544,992
Avg. Volume444,415
Market Cap8.331B
Beta1.29
PE Ratio (TTM)21.41
EPS (TTM)6.49
Earnings DateFeb 26, 2018 - Mar 2, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est178.68
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
    Markit3 days ago

    See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.

    Jazz Pharmaceuticals PLC NASDAQ/NGS:JAZZ

  • PR Newswire3 days ago

    Jazz Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference

    A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.  Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. An archive of the webcast will be available for at least one week following the presentation on the Investors section of the company's website at www.jazzpharmaceuticals.com. Jazz Pharmaceuticals plc (JAZZ) is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs.  The company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.  In these areas, Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Defitelio® (defibrotide sodium) and Vyxeos™ (daunorubicin and cytarabine) liposome for injection in the U.S. and markets Erwinase® and Defitelio® (defibrotide) in countries outside the U.S.  For more information, please visit www.jazzpharmaceuticals.com.

  • GlobeNewswire6 days ago

    Vital Therapies Appoints Russell J. Cox as Chief Executive Officer and Board Member Effective January 3, 2018

    SAN DIEGO, Dec. 04, 2017-- Vital Therapies, Inc., a biotherapeutic company developing ELAD ®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced the appointment ...

  • PR Newswire6 days ago

    Jazz Pharmaceuticals Announces Appointment Of Daniel Swisher As President And Chief Operating Officer

    DUBLIN, Dec. 4, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced the appointment of Daniel N. Swisher, Jr. as president and chief operating officer, effective January 3, 2018.  Mr. Swisher will report to Bruce Cozadd, chairman and chief executive officer.  Russell J. Cox, who has served as the company's executive vice president and chief operating officer since 2014, has resigned, effective January 3, 2018, to assume the role of Chief Executive Officer and member of the Board of Directors at a biotherapeutic company that is focused on helping patients with acute forms of liver failure.

  • Drug Charity May Shutter After U.S. Faults Pharma Influence
    Bloomberg11 days ago

    Drug Charity May Shutter After U.S. Faults Pharma Influence

    A medical charity that received hundreds of millions of dollars from pharmaceutical companies lost a crucial stamp of approval from the U.S. government, after allowing its donors improper influence over ...

  • See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
    Markit19 days ago

    See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.

    Jazz Pharmaceuticals PLC NASDAQ/NGS:JAZZ

  • See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
    Markit20 days ago

    See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.

    Jazz Pharmaceuticals PLC NASDAQ/NGS:JAZZ

  • ACCESSWIRE26 days ago

    Corporate News Blog - RXi Pharma Collaborates with Gustave Roussy, Europe's Leading Cancer Centre

    Research Desk Line-up: Jazz Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 15, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for RXi ...

  • See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
    Markit27 days ago

    See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • ACCESSWIRE27 days ago

    Featured Company News - Adaptimmune Outlines Study Designs for Two T-Cell Clinical Trials - MAGE-A4 and NY-ESO SPEAR

    Research Desk Line-up: Jazz Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 14, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Adaptimmune ...

  • See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
    Markit28 days ago

    See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of JAZZ earnings conference call or presentation 7-Nov-17 9:30pm GMT

    Q3 2017 Jazz Pharmaceuticals PLC Earnings Call

  • PR Newswirelast month

    Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences

    Jefferies London Healthcare Conference in London on Thursday, November 16, 2017 at 8:40 a.m. GMT / 3:40 a.m. EST.  Iain McGill, senior vice president, Jazz Pharmaceuticals Europe and rest of world, will provide an overview of the company and a business and financial update. Piper Jaffray 29th Annual Healthcare Conference in New York, NY on Tuesday, November 28, 2017 at 8:00 a.m. EST / 1:00 p.m. GMT.  Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update. Evercore ISI Biopharma Conference in Boston, MA on Wednesday, November 29, 2017 at 10:15 a.m. EST / 3:15 p.m. GMT.  Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update.

  • Jazz Pharmaceuticals (JAZZ) Q3 Earnings Top, 2017 View Cut
    Zackslast month

    Jazz Pharmaceuticals (JAZZ) Q3 Earnings Top, 2017 View Cut

    Jazz Pharmaceuticals (JAZZ) earnings beat estimates while revenues miss the same in Q3. The company also cuts its guidance due to lower-than-expected sales from Xyrem.

  • See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
    Markitlast month

    See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • American City Business Journals2 months ago

    All that Jazz: Why this Palo Alto drug maker is growing

    Jazz Pharmaceuticals plc is feeling the rhythm of growth. Fresh off winning Food and Drug Administration approval of a leukemia-fighting drug, the Ireland-domiciled, Palo Alto-based drug developer (JAZZ) soon will move into a new, 98,000-square-foot office building in Stanford Research Park, which it agreed to lease in early 2015 for $66 per square foot. Last month, it said it would pay more than $74 a square foot for a 100,000-square-foot structure on the site of its current home just down the street.

  • Capital Cube2 months ago

    ETFs with exposure to Jazz Pharmaceuticals Plc : October 11, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Jazz Pharmaceuticals Plc Here are 5 ETFs with the largest exposure to JAZZ-US. Comparing the performance and risk of Jazz Pharmaceuticals Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Genocea Biosciences (GNCA) Jumps: Stock Rises 24.8%
    Zacks2 months ago

    Genocea Biosciences (GNCA) Jumps: Stock Rises 24.8%

    Genocea Biosciences (GNCA) was a big mover last session, as the company saw its shares rise almost 25% on the day amid huge volumes.

  • Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : JAZZ-US : October 3, 2017
    Capital Cube2 months ago

    Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : JAZZ-US : October 3, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Jazz Pharmaceuticals Plc. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)

  • Capital Cube2 months ago

    ETFs with exposure to Jazz Pharmaceuticals Plc : September 25, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Jazz Pharmaceuticals Plc Here are 5 ETFs with the largest exposure to JAZZ-US. Comparing the performance and risk of Jazz Pharmaceuticals Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • 3 Stocks That Are Absurdly Cheap Right Now
    Motley Fool3 months ago

    3 Stocks That Are Absurdly Cheap Right Now

    Looking for value in today's pricy market? These three stocks fit the bill.

  • See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
    Markit3 months ago

    See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.

    Jazz Pharmaceuticals PLC NASDAQ/NGS:JAZZ

  • Capital Cube3 months ago

    ETFs with exposure to Jazz Pharmaceuticals Plc : September 14, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Jazz Pharmaceuticals Plc Here are 5 ETFs with the largest exposure to JAZZ-US. Comparing the performance and risk of Jazz Pharmaceuticals Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Jazz Pharmaceuticals Plc :JAZZ-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017
    Capital Cube3 months ago

    Jazz Pharmaceuticals Plc :JAZZ-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017

    Categories: Yahoo FinanceGet free summary analysis Jazz Pharmaceuticals Plc reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Jazz Pharmaceuticals Plc – Endo International Plc, Valeant Pharmaceuticals International Inc, Teva Pharmaceutical Industries Limited Sponsored ADR, Paratek Pharmaceuticals Inc, AmerisourceBergen Corporation and Novartis AG Sponsored ADR (ENDP-US, ... Read more (Read more...)

  • 3 Pharma/Biotech Sector Bargains for a Healthy Portfolio
    Zacks3 months ago

    3 Pharma/Biotech Sector Bargains for a Healthy Portfolio

    The biotech sector has turned around after its dismal performance in 2016 as uncertainty surrounding drug pricing control subsides. A few stocks are however still undervalued, which may gain going ahead.